Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - amlodipine besylate 5 mg/1 tab , perindopril arginine 10 mg/1 tab , atorvastatin calcium 20 mg/1 tab - 5 mg/1 tab , 10 mg/1 tab , 20 mg/1 tab

Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - amlodipine besylate 6.94 mg/1 tab , perindopril arginine 5 mg/1 tab , atorvastatin calcium 21.64 mg/1 tab - 6.94 mg/1 tab , 5 mg/1 tab , 21.64 mg/1 tab

Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الأدوية الأردني - the jordan drugstore co - amlodipine besylate 13.87 mg/1 tab , perindopril arginine 10 mg/1 tab , atorvastatin calcium 43 mg/1 tab - 13.87 mg/1 tab , 10 mg/1 tab , 43 mg/1 tab

Irlande - anglais - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 10 mg/5 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/5 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/10 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Irlande - anglais - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/10 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination

Irlande - anglais - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 40 mg/10 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.